These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 427766)

  • 61. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Mokyr MB
    Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.
    Weiskirch LM; Bar-Dagan Y; Mokyr MB
    Cancer Immunol Immunother; 1994 Apr; 38(4):215-24. PubMed ID: 8168116
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein.
    Freedman PM; Autry JR; Tokuda S; Williams RC
    J Natl Cancer Inst; 1976 Apr; 56(4):735-40. PubMed ID: 56452
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Importance of the concomitant presence of palpable MOPC-315 tumor in stimulation of splenocytes by C-type MOPC-315 virus in vitro.
    Schwarzbard Z; Ophir R; Gotlieb-Stematsky T; Benefraim S
    Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1069-75. PubMed ID: 2998801
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Suppressor activity of splenic macrophages in murine plasmacytoma (PC) is inhibited by PC specific ligands.
    Chen YH; Heller P
    Clin Exp Immunol; 1982 Nov; 50(2):366-73. PubMed ID: 6185260
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.
    Satoh K; Kan N; Okino T; Nakanishi M; Mise K; Teramura Y; Yamasaki S; Ohgaki K; Tobe T
    Cancer Immunol Immunother; 1991; 32(5):273-9. PubMed ID: 1998969
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.
    Röllinghoff M; Rouse BT; Warner NL
    J Natl Cancer Inst; 1973 Jan; 50(1):159-72. PubMed ID: 4571237
    [No Abstract]   [Full Text] [Related]  

  • 68. In vivo and in vitro synergistic antitumor effect of interleukin-2-cultured tumor-bearer spleen cells and immune fresh spleen cells.
    Kan N; Okino T; Nakanishi M; Satoh K; Ohgaki K; Tobe T
    Cancer Immunol Immunother; 1989; 28(4):260-6. PubMed ID: 2784714
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Role of macrophages in antitumor immunity].
    Viadro MM
    Usp Sovrem Biol; 1977; 84(5):236-47. PubMed ID: 352000
    [No Abstract]   [Full Text] [Related]  

  • 70. Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract.
    Kan N; Ohgaki K; Inamoto T; Kodama H
    Cancer Immunol Immunother; 1984; 18(3):215-22. PubMed ID: 6334553
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Augmentation of natural immunity and regulation of tumor growth by conditioning.
    Ghanta VK; Miura T; Hiramoto NS; Hiramoto RN
    Ann N Y Acad Sci; 1988; 521():29-42. PubMed ID: 3377365
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma.
    Ben-Efraim S; Shoval S; Ophir R
    Cancer Immunol Immunother; 1986; 22(1):43-8. PubMed ID: 2939947
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Alteration of cell-surface antigenicity of the mouse plasmacytoma. I. Immunologic characterization of surface antigens masked during successive transplantations.
    Ono S; Natsu-ume S; Migita S
    J Natl Cancer Inst; 1975 Sep; 55(3):569-77. PubMed ID: 51090
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes.
    Giovarelli M; Comoglio PM; Forni G
    Br J Cancer; 1976 Sep; 34(3):233-8. PubMed ID: 788762
    [TBL] [Abstract][Full Text] [Related]  

  • 75. THF-gamma 2, a synthetic thymic hormone, increases effectiveness of combined chemotherapy and immunotherapy against RPC-5 murine plasmacytoma.
    Ophir R; Pecht M; Relyveld EH; Burstein Y; Ben-Efraim S; Trainin N
    Int J Immunopharmacol; 1990; 12(7):751-4. PubMed ID: 2292455
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of solubilized membrane antigens and tumour bearer serum on tumour growth in syngeneic hosts.
    Forni G; Comoglio PM
    Br J Cancer; 1974 Oct; 30(4):365-9. PubMed ID: 4447779
    [No Abstract]   [Full Text] [Related]  

  • 77. Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.
    Bocian RC; Dray S; Ben-Efraim S; Mokyr MB
    Cancer Immunol Immunother; 1985; 20(1):61-8. PubMed ID: 3933817
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Plasmacytoma spleen colonization: a sensitive, quantitative in vivo assay for idiotype-specific immune suppression of MOPC-315.
    Daley MJ; Bridges SH; Lynch RG
    J Immunol Methods; 1978; 24(1-2):47-56. PubMed ID: 82590
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mode of action of mycobacterial fractions in antitumor immunity: preliminary evidence for a direct nonspecific stimulatory effect of MER on immunologically reactive cells.
    Weiss DW; Kuperman O; Fathallah N; Kedar E
    Ann N Y Acad Sci; 1976; 276():536-49. PubMed ID: 1071978
    [No Abstract]   [Full Text] [Related]  

  • 80. Suppression and enhancement of allografted tumour.
    Yutoku M; Seno H; Matsuoka Y; Kitagawa M
    Immunology; 1974 Mar; 26(3):623-37. PubMed ID: 4854531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.